Open access · OA
via Europe PMC
Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study.
Biomedicines · 2026
Abstract
<b>Background/Objectives:</b> Diabetic kidney disease (DKD) is a leading cause of end-stage kidney disease, and cellular senescence(definition) is a tractable therapeutic target; yet prioritizing credible repurposing candidates is difficult because bulk-tissue senescence signals are weak, single-dataset analyses are unstable, and transcriptome-reversal screens overstate novelty. The objective was to build a senescence-anchored, multi-evidence computational prioritization of repurposing candidates for DKD entirely from open data. <b>Methods:</b> Per-sample senescence activity was quantified by single-sample gene set enrichment across three DKD kidney cohorts, and consensus signatures were reversed against 45,956 LINCS L1000 signatures. Candidates were ranked by reversal strength, mechanism, ChEMBL stage, and ClinicalTrials.gov novelty, then assessed for robustness by senotherapeutic enrichment, an external senolytic benchmark, leave-one-cohort-out analysis, drug-target Mendelian randomization, and single-nucleus profiling. <b>Results:</b> Senescence activity was consistently elevated in DKD across all three cohorts, with moderate-to-large effect sizes (rank-biserial 0.32-0.78). Reversal recovered established senotherapeutic classes and nominated the approved JAK inhibitor fedratinib (within the same class, baricitinib reduced albuminuria in a Phase 2 DKD trial); curated senolytics(definition) were modestly separated from negatives (AUROC 0.62, 95% CI 0.52-0.72). Filtering yielded 867 mechanism-annotated compounds robust to cohort removal. Drug-target Mendelian randomization was inconclusive, and single-nucleus profiling highlighted endothelial activation rather than a stable senescent compartment. <b>Conclusions:</b> The result is an externally benchmarked, novelty-annotated senotherapeutic candidate map, offered as convergent confirmation of repurposable mechanisms rather than a claim of new drug classes.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.3390/biomedicines14102286
- Canonical
- link ↗
- Fetched
- 2026-10-31 MST
Cite this
APA
D, A., & Z., D. (2026). Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study. <em>Biomedicines</em>. https://doi.org/10.3390/biomedicines14102286
Vancouver
D A, Z. D. Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study. Biomedicines. 2026. doi:10.3390/biomedicines14102286.
BibTeX
@article{aygnejafari2026Senesc,
title = {Senescence-Associated Transcriptome Reversal Prioritizes Repurposing Candidates for Diabetic Kidney Disease: A Computational Study.},
author = {Aygüneş-Jafari D and Düzgün Z.},
journal = {Biomedicines},
year = {2026},
doi = {10.3390/biomedicines14102286},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Aging cell 2026
Open access · OA
Long-Term Stress Adaptation as a Highly-Conserved Key Factor in Yeast Aging.
Experimental Eye Research 2021
Citation only
Hallmarks of lens aging and cataractogenesis
Molecular Biomedicine 2025
Open access · CC-BY
Klotho antiaging protein: molecular mechanisms and therapeutic potential in diseases
npj Aging 2026
Open access · CC-BY
Frailty-related plasma metabolomic signatures predict long-term mortality risk and implicate systemic aging pathways: evidence from a prospective cohort study
Genome Research 2022
Preprint · OA
Dynamic regulation of gonadal transposon control across the lifespan of the naturally short-lived African turquoise killifish
bioRxiv (Cold Spring Harbor Laboratory) 2022
Preprint · CC-BY